Publication:
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation

dc.contributor.authorNozal, Vanesa
dc.contributor.authorFernández-Gómez, Paula
dc.contributor.authorGarcía-Rubia, Alfonso
dc.contributor.authorMartínez-González, Loreto
dc.contributor.authorCuevas, Eva P
dc.contributor.authorCarro, Eva
dc.contributor.authorPalomo, Valle
dc.contributor.authorMartínez, Ana
dc.contributor.funderAgencia Estatal de Investigación (España)es_ES
dc.contributor.funderFundación La Caixaes_ES
dc.contributor.funderLuzón foundationses_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.date.accessioned2024-05-13T07:35:16Z
dc.date.available2024-05-13T07:35:16Z
dc.date.issued2024-04-24
dc.description.abstractMultitarget ligands (MTLs) have emerged as an interesting alternative for addressing complex multifactorial pathologies such as neurodegenerative diseases. However, a common challenge associated with these compounds is often their high molecular weight and low solubility, which becomes a hurdle when trying to permeate over the blood-brain barrier (BBB). In this study, we have designed two new MTLs that modulate three pharmacological targets simultaneously (tau, beta-amyloid and TAR DNA-binding protein 43). To enhance their brain penetration, we have formulated organic polymeric nanoparticles using poly(lactic-co-glycolic acid). The characterization of the formulations, evaluation of their permeability through an in vitro BBB model, and assessment of their activity on disease-representative cellular models, such as Alzheimer's disease and amyotrophic lateral sclerosis, have been conducted. The results demonstrate the potential of the new MTLs and their nanoparticle encapsulation for the treatment of neurodegenerative diseases.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by AIE (grant PID2019–105600RB-I00), La Caixa and Luzón foundations (grant HR21-00937) and MCIN/AEI/10.13039/501100011033 (grant RYC2019-027489-I).es_ES
dc.format.page116626es_ES
dc.format.volume175es_ES
dc.identifier.citationBiomed Pharmacother. 2024 Apr 24:175:116626.es_ES
dc.identifier.doi10.1016/j.biopha.2024.116626es_ES
dc.identifier.e-issn1950-6007es_ES
dc.identifier.journalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapiees_ES
dc.identifier.pubmedID38663103es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19370
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019–105600RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2019-027489-Ies_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.biopha.2024.116626es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectMultitarget ligandes_ES
dc.subjectBlood-brain barrieres_ES
dc.subjectNanoparticleses_ES
dc.subjectProtein kinase inhibitorses_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectAmyotrophic lateral sclerosises_ES
dc.titleDesigning multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulationes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication8421fdf3-fae7-41aa-a4c1-8656ef386e2b
relation.isAuthorOfPublication.latestForDiscovery8421fdf3-fae7-41aa-a4c1-8656ef386e2b

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
DesigningMultitargetLigandsNeurodegenerativeDiseases_2024.pdf
Size:
3.62 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Supplementary_DesigningMultitargetLigandsNeurodegenerativeDiseases_2024.pdf
Size:
696.28 KB
Format:
Adobe Portable Document Format
Description:
supplementary material